W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies
X

2019 performance

Reports on healthcare service assessment – prepared in 2019

Qualification of healthcare services into the health benefit package:

  • prosthetic restoration supported by implants with postoperative control and possible need to remove implants in patients:

– after oncological treatment in the craniofacial area ICD-10: C:C00, C01, C02, C03, C04, C06, C08, C09, C10, C11, ICD9: 27.3, 27.32, 76.01, 76.01, 76.011, 76.2, 76.3, 76.31, 76.311, 76.312, 76.391, 76.4,

– with congenital craniofacial defects ICD-10: K07.0, K07.1, K07.5, Q37.0, Q37.1, Q37.8, Q37.9, Q38.6, Q67.0, Q67.4, Q75.0-Q75.9, Q87.0, ICD 9: 27.541, 27.542, 76.6, 76.69, 76.9 in the dental medicine;

  • upper complete overdenture based on protected roots. Lower complete overdenture based on protected roots in dental medicine;
  • relaxing bite splint in dental medicine;
  • panoramic radiograph with a description performed on the basis of a referral together with a justification for performance of the imaging, in connection with another dental service, 1 radiograph once every 2 years (for root canal treatment in adults) in the dental medicine;
  • X-ray diagnostics – a panoramic radiograph with a description once every 5 years in dental medicine;
  • testing by microarray-based comparative genomic hybridisation (aCGH) in outpatient specialist care (AOS);
  • daily long-term medical care as part of nursing care and services in long-term care.

Removal of healthcare services from the health benefit package:

  • removal of procedures from hospital treatment (orthopaedics and traumatology of movement) (according to ICD-9):

– 84.502 – introduction of autologous growth factors,

– 84.503 – introduction of stem cell growth factors.

Change of health technologies:

  • in the following oncological indications: C18, C19, C20, C21 colorectal neoplasms in the primary health care, outpatient specialist care, hospital treatment;
  • in the following oncological indications: C61 – prostate cancer in the primary health care, outpatient specialist care, hospital treatment;
  • in the scope of neurological rehabilitation;
  • in the scope of cardiovascular rehabilitation;
  • in the scope of systemic rehabilitation;
  • in the scope of pulmonary rehabilitation;
  • in the scope of paediatric rehabilitation.

Changes in organisation of service provision:

  • development (in consultation with stakeholders) of comprehensive oncological care in colorectal neoplasms;
  • development (in consultation with stakeholders) of comprehensive oncological care in prostatic neoplasms;
  • development (in consultation with stakeholders) of comprehensive oncological care in haematological neoplasms in adults.